APIMEDS PHARMACEUTICALS US, INC. Diluted Shares Outstanding (Weighted Average)
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Diluted Shares Outstanding (Weighted Average) of 1.71 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 1.71M shares, a 65.24% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 15.51M shares, a 96.28% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 12.60M shares, a 59.43% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 12.58M shares, a 59.11% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 10.88M shares, a 37.68% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 7.90M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 1.71M shares 10-Q · filed 2026-08-14 | 1.63M shares 10-Q · filed 2026-08-14 | 9.94M shares derived: average of 3 quarters · filed 2026-08-14 | 10.60M shares derived: average of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | 15.51M shares 10-Q · filed 2026-05-26 | 14.06M shares derived: average of 2 quarters · filed 2026-05-26 | 13.56M shares derived: average of 3 quarters · filed 2026-05-26 | 10.43M shares derived: average of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | 12.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | 12.59M shares derived: average of 2 quarters · filed 2026-05-04 | 8.74M shares derived: average of 3 quarters · filed 2026-08-14 | 10.88M shares 10-K · filed 2026-05-04 | ||
| 2025-09-30 | 12.58M shares 10-Q · filed 2025-11-12 | 6.81M shares derived: average of 2 quarters · filed 2026-08-14 | 10.31M shares 10-Q · filed 2025-11-12 | 7.36M shares derived: average of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | 1.04M shares 10-Q · filed 2026-08-14 | 10.37M shares 10-Q · filed 2025-08-19 | 915.02K shares 10-Q · filed 2026-08-14 | 9.15M shares 10-Q · filed 2025-08-19 | 5.61M shares derived: average of 3 quarters · filed 2026-08-14 | 6.19M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 7.90M shares 10-Q · filed 2026-05-26 | 7.90M shares derived: average of 2 quarters · filed 2026-05-26 | 7.90M shares derived: average of 3 quarters · filed 2026-05-26 | 7.90M shares derived: average of 4 quarters · filed 2026-05-26 | ||
| 2024-12-31 | 7.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | 7.90M shares derived: average of 2 quarters · filed 2026-05-04 | 7.90M shares derived: average of 3 quarters · filed 2026-05-04 | 7.90M shares 10-K · filed 2026-05-04 | ||
| 2024-09-30 | 7.90M shares 10-Q · filed 2025-11-12 | 7.90M shares derived: average of 2 quarters · filed 2025-11-12 | 7.90M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 7.90M shares 10-Q · filed 2025-08-19 | 7.90M shares 10-Q · filed 2025-08-19 | ||||
| 2024-03-31 | 7.90M shares 10-Q · filed 2025-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |